Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Acura Pharmaceuticals, Inc.    ACUR

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Acura Pharmaceuticals, Inc. : Analysis Reports On Active Stocks: (NASDAQ: ACUR), (NYSE: SMFG)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2013 | 07:40pm CEST

New York (April 25th, 2013) - Acura Pharmaceuticals Inc. (NASDAQ: ACUR) traded in the range of $2.56 and $2.74 during its latest trading session. The stock recorded the volume of 329,570 shares. Currently, it is at $2.68, up 3.67 from its previous close. Its average daily trading volume stands at 763,216 shares. Its MACD chart shows bullish trend. The company?s current market capitalization stands at $123.15 million.

Acura Pharmaceuticals stock has traded in the range of $1.06 and $4.50 in the past 52 weeks and has lost 17.13 percent of its value in the same time period. The stock has low volatility as its beta stands at 0.86.

Find out what could be next for ACUR here:

http://www.wallstreetscoop.net/market-scan/?symbol=ACUR


Sumitomo Mitsui Financial Group Inc. (NYSE: SMFG) stock is at $9.41, up 3.63 percent from its previous close of $9.08. The stock shows bullish trend as it made the up move with trading volume of 4.484 million shares, in contrast to the average daily trading volume of 2.044 million shares. Its bullish trend is further confirmed by its MACD chart and the stock is also trading in line with its 20 days SMA of $9.41.

Sumitomo Mitsui Financial stock is mildly volatile with its beta at 1.03. The company?s market capitalization is at $63.70 billion.

Find out more on SMFG here:

http://www.wallstreetscoop.net/market-scan/?symbol=SMFG

About Us:

WallStreetScoop.net issues momentum alerts on stocks that can provide gains to day traders and short-term investors. WallStreetScoop.net provides members with timely information and exclusive alerts on under-valued stocks in the United States with the potential to deliver short-term gains.

WallStreetScoop.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetScoop.net is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading small cap stocks. Gain an Edge by joining the WallStreetScoop.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Scoop believes traders should have a chance at successfully trading Small stocks and invites traders and investors to be part of the free membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.WallStreetScoop.net

Disclosure: WallStreetScoop.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetScoop.Net website, for complete risks and disclosures.

Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

For full disclaimer visit: www.wallstreetscoop.net/disclaimer/

Contact Info:
Thomas Greene
Wall Street Scoop
info@wallstreetscoop.net
347-905-5009


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACURA PHARMACEUTICALS, INC
08/16 ACURA PHARMACEUTICALS, INC : Notice of Delisting or Failure to Satisfy a Continu..
08/08 ACURA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
08/08 ACURA PHARMACEUTICALS, INC : Results of Operations and Financial Condition, Fina..
08/08 ACURA PHARMACEUTICALS : Announces Second Quarter 2016 Financial Results
07/28 ACURA PHARMACEUTICALS : "Methods and Compositions for Self-Regulated Release of ..
07/13 ACURA PHARMACEUTICALS, INC : Regulation FD Disclosure (form 8-K)
07/11 ACURA PHARMACEUTICALS : to Host Webcast on July 14, 2016 to Discuss Additional D..
06/08 ACURA PHARMACEUTICALS, INC : Regulation FD Disclosure, Other Events, Financial S..
06/08 ACURA PHARMACEUTICALS : Pharmaceutical's LIMITX(TM) Technology Successfully Conf..
06/02 EGALET : Purdue Pharma Announces Patent Agreement with Egalet and Acura
More news
Sector news : Bio Therapeutic Drugs
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2015 PREMARKET BIOTECH DIGEST : SA Author On Valeant, Stocks Tumble, Novartis Promact..
2015 Acura Pharma plans 1-for-5 reverse split
2015 Acura Pharmaceuticals' (ACUR) CEO Bob Jones Discusses Q2 2015 Results - Earni..
2015 PREMARKET BIOTECH DIGEST : My Investment Strategy, Geron Updates, Regeneron Earn..
2015 Acura Pharmaceuticals misses by $0.03, misses on revenue
Advertisement
Financials ($)
Sales 2016 0,90 M
EBIT 2016 -12,5 M
Net income 2016 -13,5 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 21,3x
Capi. / Sales 2017 1,59x
Capitalization 19,1 M
More Financials
Chart ACURA PHARMACEUTICALS, INC
Duration : Period :
Acura Pharmaceuticals, Inc Technical Analysis Chart | ACUR | US00509L7038 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus BUY
Number of Analysts 2
Average target price 6,00 $
Spread / Average Target 273%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert B. Jones President, Chief Executive Officer & Director
Peter A. Clemens CFO, Secretary, SVP & Head-Investor Relations
Albert W. Brzeczko Vice President-Technical Affairs
William G. Skelly Independent Director
Immanuel Thangaraj Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACURA PHARMACEUTICALS,..35.56%19
AMGEN, INC.6.90%129 863
GILEAD SCIENCES, INC.-20.33%106 391
CELGENE CORPORATION-11.23%82 402
REGENERON PHARMACEUTIC..-25.56%42 552
VERTEX PHARMACEUTICALS..-29.83%21 876
More Results